CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 117 enrolled
Drug / intervention
LAF237 (vildagliptin) +1 moredrug
Likely dose
LAF237 (vildagliptin) 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01766778
NCT01766778Phase 4Completed
CompareCT.gov

A Local Phase IV, Multicenter, Open-label Study to Evaluate Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Novartis Pharmaceuticals·interventional·Posted Jan 11, 2013·Updated May 15, 2017

In Brief

A Phase 4 clinical trial evaluating LAF237 (vildagliptin) and Metformin for Type-2 Diabetes Mellitus. Completed, enrolled 117 participants across 4 sites.

Detailed Summary

The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType-2 Diabetes Mellitus
CountriesHong Kong
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2013
Enrollment StartMay 13, 2013
Primary CompletionOct 22, 2015
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.5 years ago

Interventions

LAF237 (vildagliptin)drug

Vildagliptin 50mg capsule

Metformindrug

Metformin maximum tolerance dose